Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Breast Cancer Res Treat. 2015 Mar 19;150(3):487–499. doi: 10.1007/s10549-015-3339-x

Figure 5.

Figure 5

PELP1 is phosphorylated upon DNA damage at Ser1033 in TNBC cells. (A, B) MDA-MB-231 cells (A) and MDA-MB-468 cells (B) were treated with 1µM of camptothecin for 2 and 12 h, and total lysates were analyzed for PELP1 phosphorylation using phospho-PELP1 ser1033 specific antibody (p-PELP1). (C - F) MDA-MB-231 cells were transfected with stealth siRNA specific to PELP1 to reduce endogenous PELP1. After 48 h, the cells were transfected with siRNA-resistant GFP-PELP1 or GFP-PELP1S1033A-expressing plasmids. After 24 h, the cells were treated with DMSO or 1µM of camptothecin for 24 h. Knockdown of endogenous PELP1 was determined by Western blotting (C). GFP-PELP1, E2F1, and Actin levels were determined by Western blotting (D). qRT-PCR was used to determine Bim, Noxa (E), and Cdc25c (F) expression. ***, p<0.001.